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Objectives: To determine the clinical effectiveness of denosumab (DEN), raloxifene (RLX), 
romosozumab (ROMO) and teriparatide (TPTD), within their licensed (or anticipated licensed) 
indications, for the treatment of osteoporosis.  
Methods: A systematic review was conducted. Nine electronic databases and trial registries were 
searched up to the end of July 2018. Studies were eligible for inclusion if they were randomised 
controlled trials (RCT) in a population at risk of osteoporotic fracture, comparing these four non-
bisphosphonates DEN, RLX, ROMO, or TPTD with each other, a non-active treatment, or the 
bisphosphonates alendronate (ALN), risedronate (RIS), ibandronate (IBN) and zoledronic acid (ZOL). 
Quality of included studies was assessed using the Cochrane Risk of Bias tool. Network meta-
analyses (NMA) were used to determine the relative effectiveness of treatments. 
Results: The systematic review identified 7,898 citations. Forty-six RCTs of non-bisphosphonates met 
the inclusion criteria for the review and provided data for analyses. Additionally 49 RCTs of 
bisphosphonates were used in the NMAs. Forty-six RCTs were included in the NMA of vertebral 
fracture data, 23 RCTs for hip fractures and 73 RCTs in the NMA of femoral neck bone mineral 
density (FN BMD). For vertebral fractures, all four non-bisphosphonates showed statistically 
significant benefit relative to placebo: TPTD HR 0.23 (95% credible internal (CrI) 0.16, 0.32); ROMO 
followed by ALN 0.25 (95% CrI 0.15, 0.43); DEN HR 0.30 (95% CrI 0.21, 0.43); RLX HR 0.61 (95% CrI 
0.44, 0.80). The four non-bisphosphonates interventions studied also showed statistically significant 
benefit relative to placebo for FN BMD, and for hip fractures TPTD, ROMO followed by ALN, and DEN 
showed statistically significant benefit relative to placebo.  
Conclusions: The four non-bisphosphonate interventions studied were all clinically effective for 
reducing vertebral fractures when compared to placebo, and were beneficial for change in FN BMD 








The World Health Organization defines osteoporosis as low bone mass and microarchitectural 
deterioration of bone tissue, with consequent bone fragility and increased susceptibility to fracture. 
(1) Osteoporotic, or fragility, fractures can be considered those that result from low energy trauma 
that would not ordinarily result in fracture, or alternatively the type of fracture that increases with 
frequency the lower the bone mineral density.(2) Low energy trauma may be quantified as forces 
equivalent to a fall from standing height or less.(1, 3)  
Hip fractures are a major concern as they are associated with high rates of disability (50%) and 
mortality (20%), however these are rarely the primary endpoints of trials, with the more commonly 
occurring vertebral fracture more readily allowing statistically significant differences between groups 
to be shown. (3) (4)  There is an established association between vertebral fractures and both bone 
mineral density (BMD) and other osteoporotic fractures.(2, 3) Fragility fractures can cause pain and 
disability, impacting health-related quality of life, and vertebral fractures are associated with 
curvature of the spine and height loss, and decreased life expectancy. (1, 3)  
Treatments for osteoporosis include the anti-resorptive agents bisphosphonates, denosumab (DEN), 
raloxifene (RLX); and bone-forming agents teriparatide (TPTD) and romosozumab (ROMO). This 
review formed part of a wider project looking at non-bisphosphonates for the prevention of 
osteoporotic fragility fractures, that included non-vertebral fracture and adverse event data as well 
as an evaluation of cost-effectiveness.(5) The objective of the present study was to assess the clinical 
effectiveness of the non-bisphosphonates DEN, RLX, ROMO, and TPTD. This was addressed by 
systematic review of the evidence, and conducting a network meta-analysis (NMA) of these non-
bisphosphonates, non-active treatment, and the bisphosphonates alendronate (ALN), risedronate 






2. Materials and methods 
 
2.1 Review methods 
A systematic review was undertaken in accordance with the general principles recommended in the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.(6) (7) A 
comprehensive search was undertaken to systematically identify clinical effectiveness literature 
relating to the non-bisphosphonates DEN, RLX, ROMO, and TPTD, and the comparator 
bisphosphonates ALN, IBN, RIS and ZOL, within their European Medicines Agency (EMA) licensed 
indications for the prevention of osteoporotic fragility fractures. At the time of searches, ROMO was 
under application to the EMA. The decision was taken to include ROMO for one year, or the 
sequence of therapy ROMO for one year followed by anti-resorptive (its anticipated licensed 
indication (and, following searches, in line with the Food and Drug Administration licence 2019) (8)). 
Searches were undertaken in the following databases up to the end of July 2018: MEDLINE (via 
Ovid); Embase (via Ovid); Cochrane Database of Systematic Reviews; Database of Abstract of 
Reviews of Effects (via Wiley); Cochrane Central Register of Controlled Trials (via Wiley); Health 
Technology Assessment Database (via Wiley); Web of Science Citation Index Expanded (Clarivate 
Analytics); Web of Science Conference Proceedings Citation Index (Clarivate Analytics); WHO 
International Clinical Trials Registry Platform (full search strategy available from Davis et al 2018. (5, 
9)).The reference lists of systematic reviews and included RCTs were checked to identify any 
additional trials meeting the inclusion criteria, and bisphosphonate studies were identified from 
NICE technology appraisal 464.(10) 
All records identified by the search were screened by one reviewer, and ten percent screened by a 
second reviewer. Studies were included if they were randomised controlled trials (RCTs) of adults at 
risk of osteoporotic fragility fracture, according to the recommendations in NICE clinical guideline 
146.(3)  The interventions were DEN, RLX, ROMO, and TPTD compared against each other, the 
bisphosphonates ALN, RIS, IBN and ZOL, or a non-active treatment. The outcomes were vertebral or 
hip fractures assessed as either efficacy or safety endpoint, and bone mineral density at the femoral 
neck (FN BMD). Vertebral fractures could be assessed either radiographically or clinically, and FN 
BMD was measured by dual energy X-ray absorptiometry (DXA). Where studies planned treatment 
sequences or open-label extensions with participants in allocated randomised groups, these were 
included. Studies were excluded if the population was not at risk of osteoporotic fracture, or was a 
cancer population for which NICE guidelines already exist (11) (12), interventions were not 
administered in accordance with their licensed indications, insufficient details were reported to 
allow an assessment of study quality or results, or the RCT was published only in languages other 
than English. In addition, RCTs of bisphosphonates versus each other or placebo were sought to 
populate the NMA.  
Data relevant to the decision problem were extracted by one reviewer, without blinding to authors 
or journal, and checked by a second reviewer. Discrepancies were resolved by discussion. 
Methodological quality of RCTs identified for inclusion was assessed using the Cochrane 






2.2 Methods for the network meta-analysis 
 
NMAs were conducted, with treatment effects presented as hazard ratios (HR) relative to placebo, 
for vertebral or hip fractures. A HR less than one reflected a reduced risk of fracture relative to the 
comparator treatment. For FN BMD, treatment effects are presented as the difference in mean 
percentage change from baseline in BMD relative to placebo after 1.6 years follow-up (the average 
duration of follow-up in these studies). 
Where studies reported fractures at more than one follow-up point, the longest duration of follow-
up was used. To account for different lengths of follow up across the trials, the NMA model assumed 
an underlying Poisson process for each trial arm, with constant event rate. (14) Both radiologically 
and clinically assessed vertebral fractures were included in the main analysis. Where a study 
reported both methods, the radiologically assessed fracture data were used. 
Unrelated treatment effects were assumed for all non-bisphosphonate interventions. Exchangeable 
treatment effects (i.e. a class effect) were assumed for bisphosphonate treatments, whereby 
individual treatment effects are estimated for each bisphosphonate treatment, but these are 
assumed to arise from a common distribution (or class), as previously conducted for NICE technology 
appraisal 464. (10, 15) 
Between study heterogeneity for fracture outcomes (i.e. binomial data), as shown by the standard 
deviation (SD) in treatments effects between studies, was characterised as being mild (SD <0.1) 
ﾏﾗSWヴ;デW ふヰくヱ г SD а ヰくヵぶが ｴｷｪｴ ふヰくヵ г SD а ヱぶ ﾗヴ W┝デヴWﾏWﾉ┞ ｴｷｪｴ ふдヱぶく Meta-regression was conducted 
to explore heterogeneity in treatment effects. The node splitting method (16) was used to identify 
potential inconsistency between direct and indirect evidence. 
All analyses were conducted in the freely available software package WinBUGS(17) and R,(18) using 
the R2Winbugs(19) interface package.  Convergence to the target posterior distributions was 
assessed using the Gelman-Rubin statistic, as modified by Brooks and Gelman, (20)  for two chains 
with different initial values. For all outcomes, a burn-in of 75,000 iterations of the Markov chain was 
used with a further 20,000 iterations retained to estimate parameters. Samples from the posterior 
distributions exhibited moderate correlation between successive iterations of the Markov chain so 
were thinned by retaining every 15th sample.  
The absolute goodness of fit was checked by comparing the total residual deviance to the total 
number of data points included in an analysis. The deviance information criterion (DIC) provides a 
relative measure of goodness-of-fit that penalises complexity and was used to compare different 
models for the same likelihood and data. (21) Lower values of DIC are favourable, suggesting a more 
parsimonious model. 
Results are presented using the posterior median treatment effects, 95% credible intervals (CrI) and 
95% prediction intervals (PrI). The probability of each intervention ranking was computed by 
counting the proportion of iterations of the Markov chain in which each intervention had each rank. 
The treatment effects of each intervention compared to placebo, together with the median rank and 
probability of being the highest-ranking treatment, are displayed in forest plots. 
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In addition to the main analysis, four sensitivity analyses were undertaken for vertebral fracture 
data. The first explored the impact of fracture assessment method by restricting to fracture data 
assessed clinically, that is radiologically assessed fracture data were excluded. The second explored 
the assumption that the fracture event rate in each study arm is constant over time. For this 
sensitivity analysis, only fracture data reported at 12 months follow-up was included. The third 
sensitivity analysis excluded RCTs considered at high risk of bias by being open label, terminating 
early, or requiring estimation of number of events or denominators for a study arm from reported 
percentages or graphical images. Finally, the effect of prior treatment was considered by excluding 






3.1 Search results 
A total of 7,898 citations were identified by the searches. Study selection is shown in Figure 1. At 
abstract sift, 7,813 were excluded. At full text sift 39 RCTs were excluded (see supplementary 
material Table S1). 
Forty-six RCTs of non-bisphosphonates met the inclusion criteria for the review (shown in 
supplementary material Table S2). Additionally 49 trials of bisphosphonates were identified that 
provided data to the NMAs (shown in supplementary material Table S3).  
The majority of included trials typically excluded people with underlying conditions that influence 
bone metabolism, or who were receiving medications that influence bone metabolism. Most studies 
had a population of women with postmenopausal osteoporosis. 
Risk of bias of the non-bisphosphonate trials was assessed by the Cochrane risk of bias tool (Figure 
S1 in supplementary material). There was unclear reporting of randomisation sequence in 63% 
included RCTs but low risk of bias for 37% (Figure S1a). Allocation concealment was at low risk of 
bias in 39% RCTs and unclearly reported in 59% RCTs (Figure S1a). There was a risk of bias from lack 
of blinding of patients and clinicians in 30% RCTs (Figure S1a). For studies reporting fracture data, 
outcome assessors were reported as blinded in 53% RCTs; incomplete outcome data, defined as 
attrition of 10% or more, was reported for 46% of the RCTs. For studies reporting FN BMD data, 
outcome assessors were reported as blinded in 32% RCTs; incomplete outcome data, defined as 
attrition of 10% or more, was reported for 55% of the RCTs.  
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Records identified through database 
searching after duplicates removed 
(n =7,897) 
Additional records identified through 
other sources 
(n =1) 
Total records screened 
(n =7,898) 
Records excluded at title 
and abstract sift  
(n=7,813) 
 
RCTs assessed for eligibility  
(n = 85)     Studies excluded, with reasons 
   (n = 39) 
Reasons for exclusion: 
 Population outside scope n=14 
 Intervention or comparator 
outside scope n=12 
 Outcomes outside scope n=10 
 Conference abstract, insufficient 
details n=3 
 Trials included in evidence synthesis 





3.2 Results of the network meta-analysis   
 
3.2.1.1 Vertebral fracture main analysis 
Of the forty-six trials (24 non-bisphosphonate RCTs and 22 bisphosphonate RCTs) included in the 
vertebral fracture NMA, one RCT was a three arm study(22) whereas all others were two arm studies 
(shown in supplementary material). The network diagram is shown in supplementary material 
(Figure S2). There was moderate heterogeneity between studies (supplementary material Table S4). 
Figure 2 shows the hazard ratios (HR) of each treatment compared with placebo. The four non-
bisphosphonates studied all showed statistically significant benefit relative to placebo: TPTD HR 0.23 
(95%CrI 0.16, 0.32); ROMO for one year followed by ALN (ROMO/ALN) 0.25 (95%CrI 0.15, 0.43); DEN 
HR 0.30 (95%CrI 0.21, 0.43); RLX HR 0.61 (95%CrI 0.44, 0.80). The included bisphosphonate 
treatments were also associated with statistically significant benefit relative to placebo.  
TPTD had the highest probability of being the best treatment (0.38). Pairwise comparisons are 
shown in supplementary material (Table S5). TPTD was statistically significantly more effective than 
all active treatments apart from DEN, and ROMO/ALN. TPTD, ROMO/ALN and DEN were all more 
effective than one or more bisphosphonate (Table S5). 
Within the network there were 12 treatment pairs for which both direct and indirect comparison 
were available. None of the comparisons showed significant evidence of inconsistency. 
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Figure 2 Effects of treatment on vertebral fractures relative to placebo 
 





3.2.1.2 Vertebral fracture sensitivity analyses 
The sensitivity analysis which included only fractures as assessed by clinical methods included 20 
RCTs.(5)  The results were generally consistent with the main analysis, suggesting that treatment 
effect was not highly influenced by assessment being clinical or radiological. (5)  
Twenty-nine RCTs were included in the sensitivity analysis of vertebral fracture data reported at 12 
months follow-up. (5)  The results were generally consistent with the results of the main analysis, 
with the exception of the effect shown by RIS. RIS appeared to have a more beneficial treatment 
effect in the 12 month sensitivity (HR 0.44 95% CrI 0.32-0.60) compared with the main analysis (HR 
0.52 95% CrI 0.42-0.65). However, RIS had a zero probability of being the best ranking treatment in 
both analyses. As the results for the other interventions were generally consistent with the main 
analysis this sensitivity analysis was considered to support the use of a constant HR across duration 
of follow-up. 
Removing RCTs assessed to have a risk of bias (lack of blinding of patients, physicians or outcome 
assessors; incomplete reporting of data; or early termination of trial), resulted in a network of 30 
RCTs. (5)  The results were consistent with the main analysis. (5) Thirty-six RCTs had populations with 
no prior bisphosphonate treatment. This sensitivity analysis also had results consistent with the 
main analysis. (5) This suggested that treatment effect was not highly influenced by prior treatment 
with bisphosphonates.  
3.2.2 Hip fractures 
Twenty-three RCTs (of which 16 non-bisphosphonate studies and seven bisphosphonate studies) 
provided hip fracture data to the NMA, with a lower number of fractures than for the vertebral 
fracture analysis. The network diagram and pairwise comparisons are shown in supplementary 
material (Figure S2, Table S5). TPTD, ROMO/ALN and DEN were associated with beneficial treatment 
effects relative to placebo. The comparison to placebo was not statistically significant for RLX. TPTD 
was associated with the greatest effect, HR 0.35 (95% CrI: 0.15, 0.73), with the highest probability of 
being the best treatment (0.50), although there was insufficient evidence to differentiate between 
TPTD and the other active treatments.  
Within the network there were 14 treatment pairs for which both direct and indirect comparison 
were available. None of the comparisons showed significant evidence of inconsistency. There was 
moderate heterogeneity between studies (supplementary material Table S4). 
 








3.2.3 Femoral neck BMD 
Seventy-three RCTs were in the NMA of femoral neck bone mineral density (FN BMD) of which 38 
were non-bisphosphonate studies, and 35 were bisphosphonate studies. The network diagram and 
pairwise comparisons are shown in supplementary material (Figure S2, Table S5). All treatments 
were associated with statistically significant beneficial treatment effects relative to placebo. ROMO 
followed by ALN (ROMO/ALN) was associated with the greatest treatment effect, mean difference 
6.08 (95% CrI: 4.25, 7.91), with the highest probability of being the best treatment (0.96), and was 
statistically significantly more effective than all active treatments. There was moderate 
heterogeneity between studies (supplementary material Table S4). 
 
Figure 4 Effects of treatment on FN BMD relative to placebo 
 
TE= Treatment effect (difference in mean percentage change from baseline in BMD relative to 
placebo after 1.6 years follow-up); CrI=credible interval; PrI=prediction interval; PB=probability of 
being the best ranking treatment 
 
There was moderate heterogeneity for all NMAs, however by meta-regression there was no 
evidence that baseline risk was a significant treatment effect modifier. Meta-regressions were 
conducted to test for different treatment effects separately according to the mean age of 
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participants in each study, and the proportion of female participants. There was no evidence that 
treatment effect varied with age or gender. Results of meta-regressions are available from Davis et 





A comprehensive search identified forty-six RCTs of DEN, RLX, ROMO and TPTD meeting the review 
inclusion criteria. Data from these RCTs, and an additional 49 RCTs of ALN, IBN, RIS and ZOL, were 
synthesised in NMAs. Most of the included RCTs were conducted in postmenopausal women, 
although there were some trials of men and steroid induced osteoporosis for interventions where 
these were licensed indications. Adverse event data were reported across RCTs but are not reported 
here (available in wider review (5)). 
All non-bisphosphonates and bisphosphonates studied showed statistically significant benefit 
relative to placebo in reducing vertebral fractures. This finding complements previous NMAs that 
have shown benefit on vertebral fracture risk for bisphosphonates, RLX, DEN and TPTD,(15) (23) (24) 
Unlike other NMAs, this article includes the newer drug ROMO within a NMA against the non-
bisphosphonates and bisphosphonates currently recommended for UK treatment. (10) (25) (26) The 
four non-bisphosphonate interventions studied were all clinically effective for change in FN BMD 
compared to placebo. Hip fractures were significantly reduced by TPTD, ROMO followed by ALN, and 
DEN compared to placebo.  
The review was limited by being restricted to English language publications, and a lack of study arms 
to connect the networks meant only one treatment sequence was  analysed. Study populations 
differed according to experience of fracture at baseline, and the review was not designed to address 
timing of treatment benefit after index fracture. Study populations were not considered separately 
by gender or age, however meta-regression found no evidence that treatment effect varied with age 
or gender. Steroid-induced osteoporosis was not considered separately. There was moderate 
heterogeneity for all NMAs, however by meta-regression there was no evidence that baseline risk 
was a significant treatment effect modifier.  The consistency between direct and indirect evidence 
was assessed and no strong evidence for inconsistency was found. Studies varied in quality according 
to blinding and attrition. However, a sensitivity analysis for vertebral fracture rate, removing lower 
quality studies from the NMA, gave results consistent with the main analysis.  
Other sensitivity analyses conducted to assess the impact of assessment method for vertebral 
fractures (radiographic or clinical), and effect of prior bisphosphonate treatment, demonstrated that 
the results of the NMA were robust to these potential issues. A sensitivity analysis of duration of 
study supported the use of a constant HR, to account for differences between trials in follow-up.  
In conclusion, TPTD, ROMO followed by ALN, and DEN were all associated with beneficial effects on 
vertebral and hip fracture risk, and FN BMD, relative to placebo. RLX was associated with beneficial 
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